Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

back to job offer list
back to clinical trials

Laurie Menger

Biography

Laurie Menger Laurie Menger is an INSERM researcher and young group leader of the Advanced-T cell therapy team (U1015) at Gustave Roussy (GR), specialized in Onco/Immunobiotechnology. She has built her career on the use of multidisciplinary approaches to conduct immunotherapeutic projects leading to translational development.

During her PhD at Gustave Roussy, she developed high-throughput videomicroscopy screening for discovering immunogenic cell death inducers among FDA-approved drugs in Guido Kroemer’s lab. At UCL cancer Institute, she set up clinically relevant protocols to inactivate immunosuppressive molecules and strengthen adoptive T cells therapies with Sergio Quezada and Karl Peggs. In 2015, she was awarded with the John Goldman prize (Blood and Marrow transplantation British Society, UK). At Institut Curie, thanks to the prestigious MSCA fellowship, she established genome-wide CRISPR-Cas9 editing of CD4 T-cell to better understand their specific regulation with Olivier Lantz. In 2019, she obtained financial support from the Agence Nationale de la Recherche Jeune chercheur (ANRJCJC) Grant and in 2021 received an ATIP-Avenir (starting package, INSERM) and Gustave Roussy starting package.

Main objectives

Her work focuses on the study of T cells biology in immunosuppressive environments through systematic and unbiased approaches to accelerate immunotherapeutic targets discovery. She is combining the latest advances in T-cell engineering, genome-scale editing technologies, metabolic and single-cell profiling in a context of therapeutic adoptive transfer against cancer. Her goal is to characterize the genes and essential parameters for the development of synthetic immunology providing a new class of effective, safe and affordable treatments for oncology.

Selected Publications

  1. Ramos RN; Missolo-Koussou Y; Gerber-Ferder Y; Bromley C; Bugatti M; Gonzalo N..ez N; Boari Tosello J; Richer W; Menger L; Denizeau J; Sedlik C; Caudana P; Kotsias F; Niborski L; Viel S; Bohec M; Lameiras S; Baulande S; Lesage L; Nicolas A; Meseure D; Vincent-Salomon A; Reyal F; Dutertre CA; Ginhoux F; Vimeux L; Donnadieu E; Buttard B; Galon J; Zelenay S ; Vermi W; Guermonprez P; Piaggio E ; Helft J. Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients. Cell. 2022. https://doi.org/10.1016/j.cell.2022.02.021
  2. Sutra Del Galy A#, Menegatti S#, Lucibello F, Fuentealba J, Helft J, Darbois A, Saitakis M, Tosello J, Rookhuizen DC, Deloger M, Gestraud P, Socié G, Amigorena S, Lantz O and Menger L*. In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4+ TH1 cell response. Sci Immunol. 2021. Dec 3;6(66):eabe8219.
  3. Lucibello F, Menegatti S, Menger L*. Methods to edit T cells for cancer immunotherapy. Methods Enzymol. 2020. Jan 631:107-135.
  4. Salou M, Legoux F, Gilet J, Darbois A, du Halgouet A, Alonso R, Richer W, Goubet AG, Daviaud C, Menger L, Procopio E, Premel V, Lantz O. A common transcriptomic program acquired in the thymus defines tissue residency of MAIT and NKT subsets. J exp Med Jan 2019 7;216(1):133-151.
  5. Menger L, Sledzinska A, Bergerhoff K, Arce Vargas F, Smith J, Poirot L, Pule M, Hererro J, Peggs KS and Quezada SA. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T cell persistence and rejection of established tumors. Cancer Res. 2016. Apr 15;76(8):2087-93
  6. Menger L, Gouble A, Marzolini M, Pachnio A, Bergerhoff K, Henry J, Smith J, Pule M, Riddell S, Quezada SA and Peggs KS. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood. 2015. Dec 24;126(26):2781-9.
  7. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G, Zitvogel L. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013 Aug;24(4):311-8.
  8. Menger L, Vacchelli E, Adjemian S, Schlemmer F, Michaud M, Sulpice E, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, Zitvogel L, Kepp O and Kroemer G. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012 Jul 18;4(143):143ra99.
  9. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy. 2012 Mar;8(3):413-5
  10. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011 Dec 16;334(6062):1573-7.

 


 

Catégorie de la page: 
La recherche